B-GAG syrup
Advertisement

The National Agency for Food and Drug Administration and Control (NAFDAC) has notified Nigerians about the illegal production and sale of unregistered B-GAG mist pot CIT syrup.

The alert was contained in a statement issued by the NAFDAC Director-General, Prof. Mojisola Adeyeye, on Sunday, June 23, 2024.

The unregistered B-GAG syrup is alleged to have been sold by a company, Babban Gida Agalawa General Enterprises.

The NAFDAC boss noted that the product presented in a pet bottle was discovered during a surveillance operation carried out by the agency’s Post Marketing Surveillance Directorate Officers in Maiduguri, Borno State, and Keffi, Nasarawa State.

Adeyeye said the product was found to be without NAFDAC registration number and a misleading label.

She noted that illegal marketing of medicines or counterfeit medicines posed a risk to public health, saying without compliance with regulatory provisions the safety, quality, and efficacy of such products were not guaranteed.

NAFDAC raids Abuja supermarkets, seizes counterfeit products

The NAFDAC DG gave the batch number of the fake product as 0070; manufacturing date as 01/02/2024; and 01/02/2027 as the expiring date.

Adeyeye also gave the address of the manufacturer as No. 883/884 Western Bypass Ring Road in Kumbosto Local Government Area of Kano State.

Adeyeye stated that NAFDAC Zonal Directors and State Coordinators had been directed to carry out surveillance with a view to mopping up the illegal products within the zones and states.

She advised consumers and caregivers to avoid the use of the B-GAG syrup, adding that all medical products must be obtained from authorised and licensed suppliers.

Adeyeye said that products’ authenticity and physical condition should be carefully checked before buying.

The NAFDAC boss also enjoined healthcare professionals and consumers to report any suspicion of either the sale of substandard and falsified medicines or medical devices to the nearest NAFDAC office.

She urged healthcare professionals and patients to report adverse events or side effects related to the use of medicinal products through NAFDAC e-reporting platforms.

She said the notice about the product would be uploaded on the World Health Organization (WHO) Global Surveillance and Monitoring System (GSMS).

The Star

Advertisement

LEAVE A REPLY

Please enter your comment!
Please enter your name here